294 related articles for article (PubMed ID: 8769190)
21. An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.
Park K; Koh YB; Kwak JY; Kim SJ; Yoon YS; Kang CM; Kim YS
Transplant Proc; 1996 Jun; 28(3):1202-3. PubMed ID: 8658627
[No Abstract] [Full Text] [Related]
22. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
Gracida C; Melchor JL
Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
[No Abstract] [Full Text] [Related]
23. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.
Sketris IS; Lawen JG; Beauregard-Zollinger L; Belitsky P; Landsberg D; Givner ML; Keown P
Transplant Proc; 1994 Oct; 26(5):2961-3. PubMed ID: 7940935
[No Abstract] [Full Text] [Related]
24. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
25. Absorption of cyclosporine Neoral early after liver transplantation: influence of bile on oral absorption.
Oldhafer K; Haller GW; Kattner A; Winkler M; Maibücher A; Färber L; Bechstein WO; Ringe B; Neuhaus P; Pichlmayr R
Transplant Proc; 1996 Aug; 28(4):2237-8. PubMed ID: 8769210
[No Abstract] [Full Text] [Related]
26. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
27. Changing stable heart transplant recipients from Sandimmune to Neoral.
Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
[No Abstract] [Full Text] [Related]
28. Conversion of cyclosporine to azathroprine in renal transplant recipients.
Bassiri A; Amiranssari B; Gol S
Transplant Proc; 1995 Oct; 27(5):2691. PubMed ID: 7482877
[No Abstract] [Full Text] [Related]
29. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
30. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
[No Abstract] [Full Text] [Related]
31. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
Pescovitz MD
Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
[No Abstract] [Full Text] [Related]
32. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients.
Stephan AG; Barbari A; Masri MA; Rizk S; Moubarak R; Frem GJ; Kamel G; Baracat-Khoury W; Karam A
Transplant Proc; 1996 Jun; 28(3):1348-9. PubMed ID: 8658688
[No Abstract] [Full Text] [Related]
33. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
Hoyer PF
Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
[TBL] [Abstract][Full Text] [Related]
34. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.
Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M
Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994
[No Abstract] [Full Text] [Related]
35. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
[No Abstract] [Full Text] [Related]
36. Pharmacoeconomics of Neoral, a new formulation of cyclosporine, in renal transplantation.
Abella I
Transplant Proc; 1996 Dec; 28(6):3131-4. PubMed ID: 8962213
[No Abstract] [Full Text] [Related]
37. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
Vathsala A; Lee WT; Jacob E; Woo KT
Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
[No Abstract] [Full Text] [Related]
38. Cyclosporine pharmacology.
Lee JI; Canafax DM
Transplant Proc; 1996 Aug; 28(4):2156-8. PubMed ID: 8769185
[No Abstract] [Full Text] [Related]
39. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
[No Abstract] [Full Text] [Related]
40. Neoral versus Sandimmune in kidney transplantation.
Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
